EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

Call Career Development Fellowship (CDF)
Programme EDCTP2
Start Date 2021-01-01
End Date 2023-12-31
Project Code TMA2019CDF-2780
Status Active


Approaches to investigate pharmacokinetic mismatch and its effect on resistance acquisition in M. tuberculosis

Host Organisation

Institution Country
The University of Cape Town Lung Institute (Pty) Ltd South Africa

Current Organisation

Unniversity of Cape Town Lung Institute

Current Job Title

Senior Research Officer

Students Supervised

Type Name Title University Start Date End Date
MSc Lauren Knight Dr University of Cape Town 2016 2017
PhD Ju-Wi Chang Dr University of Cape Town 2015 2020
MMed Khanyisile Dladla Dr University of Cape Town 2020 2021


Role Committee/board Start Date End Date


Institution Degree Year
University of Cape Town, South Africa PhD 2015-06-01
London School of Hygiene and Tropical Medicine, United Kingdom MSc 2005-06-01
University of Toronto, Canada BSc Honours 2003-06-01

Areas Of Specialisation

Tuberculosis (TB)




Anil Pooran
Name Country Institution
Keertan Dheda South Africa UCT Lung Institute
Taane Clark United Kingdom LSHTM
Aim 1: To investigate pharmacokinetic (PK) mismatch within TB cavities obtained from resected lungs of incurable TB patients undergoing surgery (n=30) by determining the concentrations of the WHO group A, B and C drugs (bedaquiline, delaminid, linezolid, clofazimine) at distinct biopsy points across these cavities and their relationship to genotypic and phenotypic MIC’s at the same points and in serial sputum samples Aim 2: To evaluate targeted deep sequencing for the detection of micro-heteroresistant populations in the sputum relative the site of disease (epithelial lining fluid, lung biopsies from cavity tissue; See Figure 2) in incurable TB patients undergoing lung resection (n=20).
Cape Town, South Africa
Study Design:
Prospective cohort
Aim 1 primary outcome measure: TB drug specific concentrations at anatomically distinct points in TB cavities and other lesions correlated to MICs at these equivalent points. Aim 2 primary outcome measure: correlation of genotypic resistance mutations identified in the sputum to those in the lung Other outcome measures: detection and quantification of TB drug in the exhaled breath of drug resistant TB patients compared to serum and lung tissue (Aim 1.3)
Linked Grant:
EDCTP Clinical Research & Development Fellowship
Start Date:
End Date:

Send a Message